Helical tomotherapy: an innovative radiotherapy technique for the treatment of locally advanced oropharynx and inoperable oral cavity carcinoma

Radiation Oncology

Gianluca Bellocchi³  Nicola Raffetto¹  Alberto Rocco³  Leonardo Vigna²  Sofia Fouraki¹  Michele Cianciulli⁴  Vittorio Donato⁴ 

[1] Department of Radiation Oncology, University “Sapienza”, Rome, Italy;Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy;Department of Otorhinolaryngology, San Camillo-Forlanini Hospital, Rome, Italy;Department of Radiation Oncology, San Camillo-Forlanini Hospital, Rome, Italy

关键词: Concurrent chemoradiation;    Intensity-modulated radiotherapy;    Oral cavity cancer;    Oropharyngeal cancer;    Helical tomotherapy;   

Others  :  1153117
DOI  :  10.1186/1748-717X-8-210

 received in 2012-12-05, accepted in 2013-08-25,  发布年份 2013

【 摘 要 】

Background

To report our initial clinical experience of helical tomotherapy (HT) in the treatment of locally advanced oropharynx and inoperable oral cavity cancer.

Methods

Between February 2008 and January 2011, 24 consecutive patients, 15 with oropharyngeal cancer and 9 with oral cavity cancer were treated with exclusive radiotherapy or concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) in 30 fractions scheme was prescribed to all patients, using Helical Tomotherapy. Doses administered to primary tumor, oropharynx/oral cavity and positive lymph-nodes and negative lymph-nodes were 66–67.5 Gy, 60–63 Gy and 54 Gy, respectively.

Results

Complete response rate for the oropharynx and the oral cavity group was 86.7% and 77.8%, respectively. The 1 and 2-year Overall Survival (OS) and Disease Free Survival (DFS) rate for the oropharynx group was 92.9%, 85.1%, 92.9% and 77.4% respectively. For the oral cavity group, 1 and 2-year OS and DFS rates were 55.6%, 55.6%, 75% and 75%, respectively. No patient developed grade ≥3 mucositis, dysphagia or dermatitis. The maximum late-toxicity grade observed was 2, for all the variables examined.

Conclusions

HT appears to achieve encouraging clinical outcomes in terms of response, survival and toxicity rates.

【 授权许可】

   
2013 Donato et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150.
• [2]Working IARC: Group, Lyon, 13–20 October 1987. Alcohol drinking. IARC Monogr Eval Carcinog Risks Hum 1988, 44:1-378.
• [3]IARC Working Group: Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004, 83:1-1438.
• [4]Marur S, D'Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11(8):781-789.
• [5]Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J: Three-dimensional conformal vs. intensity-modulated radiotherapy in head and neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys 2004, 58(2):617-624.
• [6]Garden AS, Morrison WH, Rosenthal DI, Chao KS, Ang KK: Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004, 14(2):103-109.
• [7]Roe JW, Carding PN, Dwivedi RC, et al.: Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer: a systematic review. Oral Oncol 2010, 46(10):727-733.
• [8]Mackie TR, Holmes T, Swerdloff S, et al.: Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 1993, 20(6):1709-1719.
• [9]Mackie TR, Balog J, Ruchala K, et al.: Tomotherapy. Semin Rad Oncol 1999, 9:108-117.
• [10]Gregoire V, De Neve W, Eisbruch A, Lee N, Van Denweyngaert D, Van Gestel D: Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 2007, 12(5):555-564.
• [11]Chao KS, Majhail N, Huang CJ, et al.: Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001, 61:275-280.
• [12]Chao KS, Ozyigit G, Blanco AI, et al.: Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004, 59(1):43-50.
• [13]Shueng PW, Wu LJ, Chen SY, et al.: Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result. Int J Radiat Oncol Biol Phys 2010, 77(3):715-721.
• [14]Denis F, Garaud P, Bardet E, et al.: Final results of the 94–01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004, 22(1):69-76.
• [15]Sheng K, Molloy JA, Read PW: Intensity-modulated radiation therapy (IMRT) dosimetry of the head and neck: a comparison of treatment plans using linear accelerator-based IMRT and helical tomotherapy. Int J Radiat Oncol Biol Phys 2006, 65(3):917-923.
• [16]Van Vulpen M, Field C, Raaijmakers CP, et al.: Comparing step-and-shoot IMRT with dynamic helical tomotherapy IMRT plans for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005, 62(5):1535-1539.
• [17]de Arruda FF, Puri DR, Zhung J, et al.: Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006, 64(2):363-373.
• [18]Bhide SA, Gulliford S, Fowler J, et al.: Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol 2010, 97(1):86-91.
• [19]Hsieh CH, Kuo YS, Liao LJ, et al.: Image-guided intensity modulated radiotherapy with helical tomotherapy for postoperative treatment of high-risk oral cavity cancer. BMC Cancer 2011, 11:37. BioMed Central Full Text
• [20]Sher DJ, Thotakura V, Balboni TA, et al.: Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81(4):e215-e222.